Should You Buy ProQR Therapeutics NV (PRQR) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
1.600
1 Day change
-1.23%
52 Week Range
3.100
Analysis Updated At
2026/01/26
ProQR Therapeutics NV (PRQR) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators are neutral to bearish, the financial performance shows declining revenue, and there are no significant positive catalysts or trading signals to support a buy decision. Holding off for now is recommended.
Technical Analysis
The MACD histogram is negative (-0.00716) and contracting, indicating weak momentum. RSI is neutral at 50.225. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels suggest the stock is trading near its pivot (1.791), with resistance at 1.998 and support at 1.585. Overall, the technical outlook is neutral to bearish.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
The open interest put-call ratio is extremely low at 0.04, indicating a strong bias toward calls. However, today's option volume is minimal, with only 21 call contracts traded and no put volume, suggesting low activity and sentiment.
Technical Summary
Sell
10
Buy
2
Positive Catalysts
NULL identified. No recent news or significant insider or hedge fund activity. Gross margin remains at 100%, which is a positive but unchanged.
Neutral/Negative Catalysts
The stock has bearish moving averages, and there is no recent news or event-driven catalysts to drive the price upward. Additionally, the stock has a 50% chance to decline by -0.7% in the next day and -1.22% in the next month.
Financial Performance
In Q3 2025, revenue dropped to $2,915,000 (-26.78% YoY). Net income improved to -$11,006,000 (+35.74% YoY), and EPS remained flat at -0.1. Gross margin is stable at 100%. While net income improved, the overall financial performance is weak due to declining revenue.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No recent analyst ratings or price target changes are available for PRQR. Wall Street sentiment appears neutral, with no strong opinions or updates.
Wall Street analysts forecast PRQR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRQR is 7.6 USD with a low forecast of 4 USD and a high forecast of 12 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast PRQR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRQR is 7.6 USD with a low forecast of 4 USD and a high forecast of 12 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.620
Low
4
Averages
7.6
High
12
Current: 1.620
Low
4
Averages
7.6
High
12
Evercore ISI
Outperform
maintain
$4 -> $5
AI Analysis
2025-07-11
Reason
Evercore ISI
Price Target
$4 -> $5
AI Analysis
2025-07-11
maintain
Outperform
Reason
Evercore ISI raised the firm's price target on ProQR Therapeutics to $5 from $4 and keeps an Outperform rating on the shares. The firm adjusted price targets in Smid-cap biotechnology as part of a research note discussing 2026 stock ideas. There is a "notable lengthening" of time horizons among investors, which is a positive sign for the broader small cap biotech markets, the analyst tells investors in a research note.
Oppenheimer
Andreas Argyrides
Outperform
downgrade
$15 -> $9
2025-05-13
Reason
Oppenheimer
Andreas Argyrides
Price Target
$15 -> $9
2025-05-13
downgrade
Outperform
Reason
Oppenheimer analyst Andreas Argyrides lowered the firm's price target on ProQR Therapeutics to $9 from $15 and keeps an Outperform rating on the shares following quarterly results. The firm notes lead program/AX-0810 for cholestatic diseases remains on track for a 2Q25 CTA submission followed by topline data in Q4 2025 from the healthy volunteers study. Oppenheimer expects clinical candidate selection in 2025 for AX-2402/Rett Syndrome and AX-2911/MASH followed by trial initiations and topline readouts in 2026. The firm sees ProQR's initial clinical data and 2025 RNA editing catalysts re-igniting investor interest. While its fundamental outlook remains intact, negative sector sentiment continues to weigh heavily on early clinical-stage companies with no clinical data, as such, Oppenheimer increases the discount rate from 30% to 40%.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PRQR
